Registro de fonte primária
GSK apresentou uma ressubmissão de NDA para tebipenem HBr à FDA. O arquivamento aciona um pagamento de marco de $25 milhões à Spero, esperado no 1T 2026. O NDA abrange o tratamento de infecções complicadas do trato urinário, incluindo pielonefrite.
8-K NASDAQ false 0001701108 0001701108 2025-12-19 2025-12-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 675 Massachusetts Avenue , 14 th Floor Cambridge , Massachusetts 02139 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (857) 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneo